STOCK TITAN

Novocure to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Novocure (NASDAQ: NVCR) announced participation in two investor conferences: the Wells Fargo Healthcare Conference on September 7, 2022, with a fireside chat at 4:20 p.m. EDT, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022. Executive Chairman William Doyle and CFO Ashley Cordova will lead discussions, with Cordova joined by CMO Ely Benaim for additional meetings. A live audio webcast of the presentations will be available on Novocure’s Investor Relations page, with replays for 14 days.

Novocure focuses on extending survival for aggressive cancers through Tumor Treating Fields.

Positive
  • None.
Negative
  • None.

ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Executive Chairman, and Ashley Cordova, Chief Financial Officer, will participate in the 2022 Wells Fargo Healthcare Conference on September 7, 2022. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 4:20 p.m. EDT, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

Ms. Cordova will be joined by Dr. Ely Benaim, Chief Medical Officer, for additional one-on-one meetings with investors as part of the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022.

Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors:

Ingrid Goldberg

investorinfo@novocure.com

610-723-7427

Media:

Leigh Labrie

media@novocure.com

610-723-7428

Source: Novocure

FAQ

What investor conferences will Novocure participate in?

Novocure will participate in the Wells Fargo Healthcare Conference on September 7, 2022, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022.

When does Novocure's fireside chat take place?

Novocure's fireside chat at the Wells Fargo Healthcare Conference is scheduled for September 7, 2022, at 4:20 p.m. EDT.

Who will represent Novocure at the investor conferences?

William Doyle, Executive Chairman, and Ashley Cordova, CFO, will represent Novocure at the conferences, with Ely Benaim, CMO, joining for additional meetings.

How can I access Novocure's conference presentations?

The conference presentations can be accessed via the Investor Relations page on Novocure's website, with a live audio webcast available and replays for 14 days.

What is the focus of Novocure's research?

Novocure focuses on developing therapies for aggressive cancers, specifically using Tumor Treating Fields, and has products approved for glioblastoma and malignant pleural mesothelioma.

NovoCure Limited Ordinary Shares

NASDAQ:NVCR

NVCR Rankings

NVCR Latest News

NVCR Stock Data

3.35B
97.93M
9.26%
87.34%
5.24%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ST. HELIER